Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
CI · NYSE · Healthcare
Fundamental quality
58
out of 100
Cigna Group earns a fundamental-quality score of 58 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its financial strength (net debt 2.02× EBITDA). Its weakest area is its growth (revenue +10.8%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Cigna is a U.S. healthcare giant with two legs: health insurance (employer and individual plans) and, above all, Evernorth, its pharmacy-services business, which manages medications for millions of people and generates most of its revenue.
EPS growth: 0.9% · Revenue growth: 10.8%
Net margin: 2.3% · ROE: 15.1% · ROIC: 11.8%
Net debt/EBITDA: 2.02x
Source: SEC EDGAR · TTM through 30/06/2026
The score includes +1 for dividend strength: 5 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 160,401 | 8,489 | — | 22,737 |
| 2021 | 174,069 | 5,420 | — | 28,589 |
| 2022 | 180,518 | 6,782 | — | 25,169 |
| 2023 | 195,265 | 5,164 | — | 23,108 |
| 2024 | 247,121 | 3,434 | — | 24,422 |
| 2025 | 274,900 | 5,957 | — | 23,787 |
Between 2020 and 2025, revenue went from $160,401M to $274,900M (+71%) and net income went from $8,489M to $5,957M (-30%). Meanwhile, its margins have narrowed (from 5% to 2%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$6.04
per share, yearly
27% of earnings
Payout
5 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Cigna Group cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Cigna Group a good company to invest in?
In terms of business quality, Cigna Group scores 58 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Cigna Group a profitable company?
Cigna Group is profitable, with a net margin of 2.3%, though a thin one.
Does Cigna Group have a lot of debt?
A moderate level: its net debt is 2.02 times its EBITDA.
Is Cigna Group growing?
Its revenue has grown 10.8% annualized in recent years and its earnings per share 0.9%, and without interruption since 2020.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Merck (MRK) · Thermo Fisher Scientific (TMO) · Abbott Laboratories (ABT) · Intuitive Surgical (ISRG) · Pfizer (PFE) · Amgen (AMGN) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Cigna Group's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.